Nektar Therapeutics (NKTR US): A Good Buying Option in Immuno-Oncology Therapeutic Area

233 Views13 Dec 2021 00:57

SUMMARY

Nektar Therapeutics (NKTR US) is a global biopharmaceutical company, with major focus on immune-oncology. Its lead candidate bempeg is the near-term growth engine for the company.
On December 6, Nektar presented favorable results for Bempeg plus Keytruda in patients with non-small-cell lung cancer. Bempeg is poised for getting approvals for multiple indications during 2023–2025.
Clinical trial progress of other late-stage programs remains long-term growth driver for Nektar. Buyout deal at a premium presents another upside opportunity for Nektar.

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network